Katherine Stueland Sells 3,639 Shares of GeneDx Holdings Corp. (NASDAQ:WGS) Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CEO Katherine Stueland sold 3,639 shares of the company’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $33.33, for a total transaction of $121,287.87. Following the transaction, the chief executive officer now owns 95,457 shares in the company, valued at approximately $3,181,581.81. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Katherine Stueland also recently made the following trade(s):

• On Monday, July 29th, Katherine Stueland sold 2,154 shares of GeneDx stock. The stock was sold at an average price of $33.54, for a total transaction of $72,245.16.
• On Monday, June 17th, Katherine Stueland sold 7,683 shares of GeneDx stock. The shares were sold at an average price of $28.31, for a total transaction of $217,505.73.

GeneDx Trading Up 4.7 %

WGS traded up $1.59 during midday trading on Wednesday, reaching $35.26. 344,758 shares of the company were exchanged, compared to its average volume of 396,852. The stock has a market capitalization of $921.06 million, a P/E ratio of -6.81 and a beta of 2.29. GeneDx Holdings Corp. has a one year low of $1.16 and a one year high of $37.45. The stock’s 50-day simple moving average is $32.49 and its 200 day simple moving average is $22.21. The company has a debt-to-equity ratio of 0.27, a quick ratio of 2.22 and a current ratio of 2.38.

GeneDx (NASDAQ:WGS) last released its quarterly earnings data on Tuesday, July 30th. The company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.15. GeneDx had a negative net margin of 48.21% and a negative return on equity of 22.71%. As a group, analysts forecast that GeneDx Holdings Corp. will post -0.75 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in WGS. Acadian Asset Management LLC acquired a new position in shares of GeneDx during the second quarter worth about $34,000. nVerses Capital LLC acquired a new position in GeneDx during the 2nd quarter worth approximately $50,000. Thompson Davis & CO. Inc. grew its stake in shares of GeneDx by 20.8% during the 1st quarter. Thompson Davis & CO. Inc. now owns 24,094 shares of the company’s stock worth $220,000 after acquiring an additional 4,150 shares in the last quarter. Decheng Capital LLC acquired a new stake in shares of GeneDx in the fourth quarter valued at approximately $285,000. Finally, The Manufacturers Life Insurance Company bought a new stake in shares of GeneDx in the second quarter worth $290,000. Institutional investors and hedge funds own 61.72% of the company’s stock.

Analyst Ratings Changes

Several research analysts have issued reports on WGS shares. Jefferies Financial Group began coverage on GeneDx in a report on Monday, June 3rd. They set a “hold” rating and a $21.00 price objective on the stock. Craig Hallum upped their price target on GeneDx from $43.00 to $46.00 and gave the company a “buy” rating in a research note on Wednesday, July 31st. TD Cowen lifted their price objective on GeneDx from $46.00 to $50.00 and gave the stock a “buy” rating in a research report on Wednesday, July 31st. The Goldman Sachs Group upped their target price on shares of GeneDx from $28.00 to $32.00 and gave the company a “neutral” rating in a research report on Wednesday, July 31st. Finally, Wells Fargo & Company started coverage on shares of GeneDx in a research report on Tuesday, August 27th. They set an “equal weight” rating and a $34.00 price target for the company. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $38.00.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.